Cannabix Technologies to Participate in October Southern US Study using Marijuana Breathalyzer Technology
In the Southern US study, Cannabix is working alongside toxicologists and law enforcement officers who are testing subjects under the influence of marijuana.
VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports it will be participating in a mid-October study date to test a supplemental version of its FAIMS technology for detection of ∆9-tetrahydrocannabinol (“THC”) and related analytes in human breath in a comprehensive multi-analysis study of subjects under the influence of marijuana in the southern United States. Cannabix has participated in two testing day events held in two different US cities in June and July. The October event will be held in a new location. In the Southern US study, Cannabix is working alongside toxicologists and law enforcement officers who are testing subjects under the influence of marijuana. The Company’s technology (proprietary breath capture and marijuana detection equipment, described below) is being used side by side with several conventional drug screening methods including blood and oral fluid collection. Furthermore, a closed course driving test is planned for the mid-October study date to gauge impairment. Details of the study will be available in due course when disclosure approvals are granted to the Company.
Data from previous studies demonstrate very consistent correlation of levels of THC in direct comparison between breath samples collected and analyzed with Cannabix hardware and the current standard of whole blood. The Company’s handheld Breath Collection Unit (“BCU”, Fig. 1) and newly developed laboratory “MS Breath Sampler” (Fig. 2) are being used together to provide a new ground-breaking method for drug detection that complements gold-standard mass spectrometry (MS) and significantly simplifies laboratory analysis methods, reduces sample turnaround times (thus minimizing operating costs), while maintaining sensitive, precise results.
The Company has developed a unique breath capture system, capable of collecting low volatility analytes, such as THC, from a sample size of only approximately 5 breaths. In addition, the Cannabix device captures analytes efficiently such that the sample preparation steps needed in traditional methods are completely eliminated. The system has detected and confirmed THC in breath out to 4 hours after smoking with breath samples being stored and analyzed up to two days after sample collection.
THC in Breath & Blood Data
Cannabix has been actively participating in breath-blood studies over the course of the year - completing experiments in Ontario (see press release from May 9th, 2022) and alongside law enforcement in the southern US in June and July (see press releases from July 12th and August 25th, 2022). The study results show that breath levels of THC over time are consistent between subjects, and data demonstrate consistent correlation of levels of THC between breath and whole blood in early time points after smoking.
Study Importance
With its participation in these blood-breath correlation studies, the Company is building an important body of real-world breath data of various cannabis users, taken using cutting-edge hardware developed by Cannabix. These data significantly increase accuracy of recency of use by metabolism measurements. Blood is currently the standard of measurement for drug determination by law enforcement and toxicologists, and is used as objective evidence of possible impairment in courts of law.
According to the NHTSA report to congress (2017)1 THC in blood drops rapidly after cessation of use. In contrast to alcohol, which is metabolized at a relatively steady rate, THC is metabolized at an exponentially declining rate, such that the THC blood level first drops rapidly, followed by a slower decline as lower THC levels are reached. Within 30 minutes of smoking, the amount of THC in blood and breath can decline as much as 80 – 90 percent from its peak level. A low level then remains for only a few hours prior to the return to baseline level. Because of this short window, confirmation of drug presence as quickly as possible after the time of a law enforcement stop is paramount to provide accurate objective evidence of recency of use of cannabis in drugged driving. Cannabix equipment can be used to collect breath samples immediately upon suspicion of impairment, and can significantly reduce the time needed throughout the drug confirmation process. Analysis times (1-2 min per sample), are much shorter than most current methods, which can improve high throughput operations and remove backlogs; also speeding up the administrative process. Cannabix devices are designed to be easy-to-use and seamlessly interfaced with techniques that toxicologists are already familiar with, requiring minimal training by all users.
Cannabix tools provide quick and nonintrusive breath sample collection and easy analysis with no sample preparation needed. In comparison, existing and legacy breath and saliva testing procedures require several sample extraction and preparation steps prior to analysis, and analysis itself can take from 1 - 3 hours per sample. This is expensive and impractical. Also, existing and legacy breath and saliva testing procedures tend to have inefficient, time-consuming collection methods, and recoveries are still often poor. Cannabix has developed unique approaches to breath testing that will reduce costs and make operations and processes far more efficient.
(1) Marijuana-Impaired Driving (nhtsa.gov)
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC - the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix devices are in the advanced prototype and pre-clinical testing stage.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that its development of marijuana breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ba4b40b-fc02-41a7-b396-046315e38f91
